

Appendix 1: Baseline characteristics of patients in the ASSENT-3 PLUS and ASSENT-3 trials, by treatment group

| Characteristic | ASSENT-3 PLUS | | | | | | ASSENT-3 | | | | | |
|----------------------------------|----------------------------|-----|----------|----------------------------|-----|----------|-----------------------------|-----|----------|-----------------------------|-----|----------|
| | Enoxaparin, <i>n</i> = 818 | | | UF heparin, <i>n</i> = 821 | | | Enoxaparin, <i>n</i> = 2040 | | | UF heparin, <i>n</i> = 2038 | | |
| | No. | %* | <i>n</i> | No. | %* | <i>n</i> | No. | %* | <i>n</i> | No. | %* | <i>n</i> |
| Age, yr, mean (SD) | 62 (13) | | | 62 (13) | | | 61 (12) | | | 61 (13) | | |
| Patients aged > 75 yr | 149 | 18 | 817 | 132 | 16 | 820 | 263 | 13 | 2040 | 271 | 13 | 2038 |
| Women | 194 | 24 | 818 | 184 | 22 | 821 | 463 | 23 | 2040 | 478 | 23 | 2038 |
| Women aged > 75 yr | 73 | 38 | 193 | 56 | 30 | 184 | 110 | 24 | 463 | 129 | 27 | 478 |
| Hypertension | 289 | 35 | 815 | 298 | 36 | 820 | 826 | 41 | 2037 | 824 | 41 | 2031 |
| Diabetes | 115 | 14 | 816 | 128 | 16 | 820 | 381 | 19 | 2039 | 363 | 18 | 2031 |
| Previous myocardial infarction | 120 | 15 | 816 | 117 | 14 | 820 | 290 | 14 | 2040 | 293 | 14 | 2035 |
| Prior CABG | 21 | 2.6 | 814 | 13 | 1.6 | 819 | 73 | 3.6 | 2038 | 53 | 2.6 | 2029 |
| Prior PCI | 60 | 7.4 | 806 | 52 | 6.4 | 816 | 126 | 6.2 | 2019 | 128 | 6.4 | 2012 |
| Current smoker | 336 | 42 | 801 | 365 | 45 | 809 | 884 | 44 | 1992 | 930 | 47 | 1988 |
| Infarct location | | | | | | | | | | | | |
| Anterior | 341 | 42 | 813 | 350 | 43 | 820 | 802 | 39 | 2040 | 772 | 38 | 2037 |
| Inferior | 439 | 54 | 813 | 444 | 54 | 820 | 1144 | 56 | 2040 | 1164 | 57 | 2037 |
| Other | 33 | 4.0 | 813 | 26 | 3.2 | 820 | 94 | 4.6 | 2040 | 101 | 5.0 | 2037 |
| Heart rate, beats/min, mean (SD) | 74 (19) | | | 74 (19) | | | 75 (17) | | | 74 (17) | | |
| Systolic BP, mm Hg, mean (SD) | 134 (25) | | | 132 (25) | | | 134 (22) | | | 133 (23) | | |
| Killip class † | 593 | 92 | 642 | 603 | 92 | 654 | 1823 | 89 | 2039 | 1786 | 88 | 2033 |

Note: ASSENT = Assessment of the Safety and Efficacy of a New Thrombolytic Agent, UF = unfractionated, SD = standard deviation, CABG = coronary artery bypass graft, PCI = percutaneous coronary intervention, BP = blood pressure.

*Unless indicated otherwise.

†Killip class was unrecorded in the records of 21% of ASSENT-3 PLUS patients.